Search results for "Selective serotonin reuptake inhibitors"

showing 10 items of 51 documents

Association Between Citalopram Serum Levels and Clinical Improvement of Patients With Major Depression

2011

Imaging studies have shown that serum concentrations of the selective serotonin reuptake inhibitor citalopram correlate with serotonin transporter (5-HTT) occupancy in vivo. In patients with major depressive disorders treated with citalopram, 80% 5-HTT occupancy was considered to be necessary for maximal therapeutic effects, which requires citalopram serum concentrations of at least 50 ng/mL. The aim of this study was to compare treatment outcome in patients with citalopram serum concentrations greater than and less than 50 ng/mL after 7 days of treatment. This study included inpatients with acute major depressive disorder according to International Classification of Disease, 10th Revision …

Malemedicine.medical_specialtySerotonin reuptake inhibitorCitalopramCitalopramSeverity of Illness Indexbehavioral disciplines and activitiesGastroenterologyInternal medicinemental disordersSeverity of illnessmedicineHumansPharmacology (medical)Adverse effectDepressive Disorder Majormedicine.diagnostic_testTherapeutic effectLength of StayMiddle Agedmedicine.diseasePsychiatry and Mental healthTherapeutic drug monitoringAnesthesiaMajor depressive disorderFemaleDrug MonitoringReuptake inhibitorPsychologySelective Serotonin Reuptake Inhibitorsmedicine.drugJournal of Clinical Psychopharmacology
researchProduct

Effect of sertraline treatment on benzodiazepine receptors in the rat brain.

1993

In this paper we describe the modification of benzodiazepine (BDZ) binding sites in the rat brain after different times of treatment with the 5-hydroxytryptamine-(5HT) uptake blocker sertraline. We investigated the effect of 8, 15 and 30 days sertraline treatment (10 mg/kg/day, i.p.) on 3 H-flunitrazepam binding sites. In order to describe the anatomical site of action of the drug, the experiment has been carried out by means of quantitative receptor autoradiography. After 8 days of sertraline treatment, an increase of BDZ receptor density is found in the olfactory tubercle. This effect is reversed at 15 and 30 days. At 15 days of treatment, an increase is found in the anterior cingulate co…

Malemedicine.medical_specialtymedicine.drug_classRats Sprague-DawleyInternal medicineSertralinemedicineLimbic SystemAnimalsReceptorBiological Psychiatry5-HT receptorBrain ChemistryCerebral CortexBenzodiazepineSertralineBehavior AnimalGABAA receptorChemistryOlfactory tubercleBody WeightSeptal nucleiOlfactory PathwaysReceptors GABA-AAntidepressive AgentsRatsPsychiatry and Mental healthmedicine.anatomical_structureEndocrinology1-NaphthylamineNeurologyAnti-Anxiety AgentsCerebral cortexNeurology (clinical)Selective Serotonin Reuptake Inhibitorsmedicine.drugJournal of neural transmission. General section
researchProduct

Intracerebral Hemorrhage and Outcome After Thrombolysis in Stroke Patients Using Selective Serotonin-Reuptake Inhibitors.

2017

Background and Purpose— Selective serotonin-reuptake inhibitors (SSRIs) impair platelet function and have been linked to a higher risk of spontaneous intracerebral hemorrhage—an association that may be augmented by oral anticoagulants (OAC). We aimed to assess whether preadmission treatment with SSRIs in patients with acute ischemic stroke is associated with post-thrombolysis symptomatic intracerebral hemorrhage (sICH) and functional outcome. Methods— A multicenter retrospective analysis was conducted in prospective registries of patients treated by thrombolysis within 4.5 hours of stroke onset. The association between preadmission treatment with SSRIs and sICH (ECASS II definition [Europe…

Malemedicine.medical_specialtytherapeutic use [Anticoagulants]medicine.medical_treatmentSubgroup analysisepidemiology [Cerebral Hemorrhage]Risk AssessmentCohort Studies03 medical and health sciencesadverse effects [Serotonin Uptake Inhibitors]0302 clinical medicineModified Rankin ScaleInternal medicinemedicineHumansThrombolytic Therapy030212 general & internal medicineddc:610610 Medicine & healthStrokeCerebral HemorrhageAgedRetrospective StudiesAdvanced and Specialized NursingIntracerebral hemorrhageAged 80 and overtherapy [Cerebral Hemorrhage]business.industryAnticoagulantsThrombolysisOdds ratioMiddle Agedmedicine.diseaseadverse effects [Selective Serotonin Reuptake Inhibitors]Prognosisdrug therapy [Stroke]StrokeTreatment OutcomeAnesthesiaConcomitantSerotonin Uptake InhibitorsFemaleNeurology (clinical)Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgerySelective Serotonin Reuptake Inhibitorsepidemiology [Stroke]Cohort study
researchProduct

Serotonin-dopamine interaction: electrophysiological evidence.

2008

In this review, the most relevant data regarding serotonin (5-hydroxytryptamine, 5-HT)/dopamine (DA) interaction in the brain, as studied by both in vivo and in vitro electrophysiological methods, are reported and discussed. The bulk of neuroanatomical data available clearly indicate that DA-containing neurons in the brain receive a prominent innervation from 5-HT originating in the raphe nuclei of the brainstem. Furthermore, this modulation seems to be reciprocal; DA neurons innervate the raphe nuclei and exert a tonic excitatory effect on them. Compelling electrophysiological data show that 5-HT can exert complex effects on the electrical activity of midbrain DA neurons mediated by the va…

NeuronsSerotoninDopamineBrainelectrophysiology dopamineSettore BIO/09 - FisiologiaElectric StimulationSerotonin Receptor AgonistsElectrophysiologyReceptors SerotoninDopamine AgonistsNeural PathwaysAnimalsDopamine AntagonistsSerotonin AntagonistsSelective Serotonin Reuptake InhibitorsProgress in brain research
researchProduct

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service.

2001

Therapeutic drug monitoring data of the new atypical neuroleptic drug olanzapine were used to study interactions with the selective serotonin reuptake inhibitors fluvoxamine and sertraline. The distribution of the ratio of concentration/daily dose (C/D; ng/mL per mg/d) of olanzapine was compared in three groups: patients treated with olanzapine (n = 134), patients treated with olanzapine plus fluvoxamine (n = 10) concomitantly, and patients treated with olanzapine plus sertraline (n = 21) concomitantly. No significant difference was seen between the olanzapine and the olanzapine plus sertraline groups. Patients receiving fluvoxamine in addition to olanzapine had C/D ratios that were in the …

OlanzapineAdultMaleFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsCytochrome P-450 Enzyme SystemSertralineMedicineHumansPharmacology (medical)Drug InteractionsAdverse effectChromatography High Pressure LiquidAgedPharmacologySertralineDepressive Disordermedicine.diagnostic_testbusiness.industryPirenzepineDrug interactionMiddle AgedLiverTherapeutic drug monitoringFluvoxamineOlanzapineAntidepressive Agents Second-GenerationFemaleDrug MonitoringbusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugTherapeutic drug monitoring
researchProduct

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects.

2002

Olanzapine is a substrate of the cytochrome P450 enzyme (CYP) 1A2. In this study, pharmacokinetic interactions and clinical effects of adding the CYP1A2 inhibitor fluvoxamine to steady-state olanzapine was examined in patients suffering from schizophrenia. Eight patients had been treated for at least 3 months with 10 to 20 mg/day olanzapine. Fluvoxamine (100 mg/day) was added (week 0) to the olanzapine treatment and continued for 8 weeks. Concentrations of olanzapine and its metabolite N-desmethylolanzapine and of fluvoxamine were analyzed at weeks 0, 1, 4, and 8. Addition of fluvoxamine resulted in a 12% to 112% (0.01) increase of olanzapine from 31 +/- SD 15 ng/mL (week 0) to 56 +/- 31 ng…

OlanzapineAdultMaleTime FactorsCombination therapyFluvoxaminePharmacologyBenzodiazepinesPharmacokineticsmedicineHumansPharmacology (medical)Drug InteractionsProspective Studiesmedicine.diagnostic_testbusiness.industryDopamine antagonistPirenzepineDrug interactionMiddle AgedPsychiatry and Mental healthTherapeutic drug monitoringChemotherapy AdjuvantFluvoxamineOlanzapineChronic DiseaseSchizophreniaFemalebusinessReuptake inhibitorSelective Serotonin Reuptake Inhibitorsmedicine.drugFollow-Up StudiesJournal of clinical psychopharmacology
researchProduct

A monoamine oxidase B gene variant and short-term antidepressant treatment response.

2007

Genetic differences among patients suffering from Major Depression are likely to contribute to interindividual differences in medication treatment response. Thus, the identification of gene variants affecting drug response is needed in order to be able to predict response to psychopharmacological drugs. This study analyzed a possible association of the common A644G single nucleotide polymorphism (SNP) within intron 13 of the monoamine oxidase B (MAOB) gene with antidepressant treatment response. The study population consisted of n = 102 patients with major depression (criteria of the Diagnostic and Statistical Manual of Mental Disorders, 4th Edition; DSM-IV) participating in a randomized do…

OncologyAdultMalemedicine.medical_specialtyMirtazapineSingle-nucleotide polymorphismMirtazapineMianserinPharmacologyDouble-Blind MethodInternal medicinemedicineHumansMonoamine OxidaseBiological PsychiatryAllelesPharmacologyPsychiatric Status Rating ScalesDepressive Disorder MajorbiologyReverse Transcriptase Polymerase Chain ReactionDNAMiddle AgedMianserinParoxetineAntidepressive AgentsIntronsParoxetineData Interpretation Statisticalbiology.proteinAntidepressantFemaleMonoamine oxidase BMonoamine oxidase APsychologyPharmacogeneticsSelective Serotonin Reuptake Inhibitorsmedicine.drugProgress in neuro-psychopharmacologybiological psychiatry
researchProduct

Antidepressant drugs and memory: Insights from animal studies

2007

This is a selective review of the literature concerning the effects of antidepressant drugs on animal memory, which was performed with the aid of the PubMed database. Monoamine oxidase inhibitors tend to either have no effect on memory or result in its improvement. Studies with cyclic antidepressants have reported no effect or, more often, memory impairments. Pre-training administration of selective serotonin reuptake inhibitors (SSRIs) has been shown to have either no effect on memory or undermine it (with some isolated exceptions, in which improvements have been recorded), while post-training administration of SSRIs has been demonstrated to improve memory or have no effect. A small group …

PharmacologyMonoamine Oxidase InhibitorsMonoamine oxidaseTrazodoneAntidepressive Agents TricyclicSerotonin reuptakePharmacologyAntidepressive AgentsRatsPsychiatry and Mental healthNeurologyMemorymedicineAnimalsConditioning OperantAntidepressantPharmacology (medical)Neurology (clinical)Animal studiesPsychologyNeuroscienceSelective Serotonin Reuptake InhibitorsBiological Psychiatrymedicine.drugEuropean Neuropsychopharmacology
researchProduct

A novel arousal-based individual screening reveals susceptibility and resilience to PTSD-like phenotypes in mice

2021

Translational animal models for studying post-traumatic stress disorder (PTSD) are valuable for elucidating the poorly understood neurobiology of this neuropsychiatric disorder. These models should encompass crucial features, including persistence of PTSD-like phenotypes triggered after exposure to a single traumatic event, trauma susceptibility/resilience and predictive validity. Here we propose a novel arousal-based individual screening (AIS) model that recapitulates all these features. The AIS model was designed by coupling the traumatization (24 h restraint) of C57BL/6 J mice with a novel individual screening. This screening consists of z-normalization of post-trauma changes in startle …

Physiology5-trial SM 5-trial social memoryBiochemistryFight-or-flight responseFST forced swim test0302 clinical medicineEndocrinologySSRIs selective serotonin reuptake inhibitorsDSM-5 Diagnostic and Statistical Manual of Mental DisordersOriginal Research ArticleFear conditioningmedia_commonHT hypothalamusAIS arousal-based individual screeningQP351-495ParoxetinePhenotypeHPA hypothalamic–pituitary–adrenalBST basal synaptic transmissionHIP hippocampusPTSD post-traumatic stress disorder[SDV.NEU]Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]Psychological resilienceAmy amygdalaRC321-571medicine.drugNeurophysiology and neuropsychologymedia_common.quotation_subjectBDNF brain derived neurotropic factorFear conditioningNeurosciences. Biological psychiatry. NeuropsychiatryBiologyStressArousal03 medical and health sciencesCellular and Molecular NeuroscienceAnimal model Fear conditioning Resilience Stress Susceptibility Z-scoreAnimal modelCORT corticosteroneOF open fieldTE trauma-exposedBiological neural networkmedicineAnimal model[SDV.NEU] Life Sciences [q-bio]/Neurons and Cognition [q-bio.NC]C controlfEPSPs field excitatory post-synaptic potentialsSGK1 serum/glucocorticoid-regulated kinase 1RC346-429Molecular BiologyResilienceEndocrine and Autonomic SystemsZ-scoremPFC medial prefrontal cortexFKBP5 FK506 binding protein 5FDA Food and Drug AdministrationASR acoustic startle reactivityEPM elevated plus maze030227 psychiatrySusceptibilityAnimal model; Fear conditioning; Resilience; Stress; Susceptibility; Z-scoreNeurology. Diseases of the nervous systemNeuroscience030217 neurology & neurosurgeryNeurobiology of Stress
researchProduct

Serotonin dysfunction syndromes: a functional common denominator for classification of depression, anxiety, and obsessive-compulsive disorder.

1993

Psychiatric Status Rating Scalesmedicine.medical_specialtyDepressive DisorderObsessive-Compulsive DisorderSerotoninCommon denominatormedicine.diseaseAnxiety DisordersSerotonin Receptor AgonistsPsychiatry and Mental healthObsessive compulsiveReceptors SerotoninPsychiatric status rating scalesmedicineAnxietyHumansPharmacology (medical)SerotoninSerotonin Antagonistsmedicine.symptomPsychiatryPsychologyAnxiety disorderDepression (differential diagnoses)Selective Serotonin Reuptake InhibitorsInternational clinical psychopharmacology
researchProduct